From the Let’s do it for ME website.
Surprising news from Norway today, but the ground-breaking work continues in UK thanks to all involved and everyone supporting Invest in ME Research, so please don’t be too disappointed, as the charity explains in the following statement published today and reposted below.
Professor Olav Mella recently publicly released early details from the Phase III multi-centre double-blinded placebo-controlled Rituximab Clinical Trial which has been ongoing in Norway for the past year.
Invest in ME Research have been informed by Dr Oystein Fluge of this.
Invest in ME Research have issued this preliminary statement (below).
The Haukeland team will be presenting at the IIMEC13 13th International ME Conference in London on 1st June 2018.
Invest in ME Research Initial Statement
on Norwegian Phase III Rituximab Clinical Trial
November 21, 2017
The statement from Haukeland University, Bergen from Professor Mella is a major disappointment for people with ME and their families.
What had looked to be a promising line of research that could lead to an effective treatment for a subgroup of patients defined by the Canadian Criteria and major understanding of the pathology of this disease has proven to be inconclusive.
Naturally, at the charity, everyone is disappointed. We are disappointed for all the ME patients and carers and families and friends.
To read the rest of this story, click on the link below: